• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

    32.55 +1.36 (+4.34%)
    Streaming Delayed Price Updated: 10:15 AM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about RAPT Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces Proposed Public Offering of Common Stock
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
    RAPT on track to initiate trial this year 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Second Quarter 2025 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Participate in Upcoming Investor Conferences
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports First Quarter 2025 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Participate in Upcoming Investor Conferences
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces $150 Million Private Placement
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Third Quarter 2024 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
    Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Second Quarter 2024 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports First Quarter 2024 Financial Results
    Company maintains solid cash position of $141.6 million 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    Company maintains solid cash position of $158.9 million 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.